{
    "subject": "Medicine",
    "author": "Archith Boloor",
    "totalChapters": 12,
    "chapters": [
        {
            "id": 1,
            "title": "Cardiology",
            "topics": [
                {
                    "id": "card-001",
                    "title": "Ischemic Heart Disease",
                    "keyPoints": [
                        "Risk factors: HTN, DM, smoking, dyslipidemia, family history, obesity, sedentary lifestyle",
                        "Pathophysiology: Atherosclerotic plaque formation → coronary artery narrowing → myocardial ischemia",
                        "Clinical presentation: Chest pain (crushing, radiating to left arm/jaw), dyspnea, diaphoresis, nausea",
                        "Diagnosis: ECG (ST changes, T wave inversion), Cardiac biomarkers (Troponin I/T, CK-MB), Coronary angiography (gold standard)",
                        "STEMI: ST elevation >1mm in 2 contiguous leads, requires immediate reperfusion",
                        "NSTEMI: Elevated troponins without ST elevation, managed with antiplatelet therapy",
                        "Unstable angina: Ischemic symptoms without biomarker elevation",
                        "Acute management: MONA (Morphine, Oxygen, Nitrates, Aspirin) + Dual antiplatelet therapy",
                        "Reperfusion: Primary PCI (preferred if <90 min) or Thrombolysis (if PCI not available)",
                        "Secondary prevention: Aspirin + P2Y12 inhibitor, Beta-blockers, ACE inhibitors, Statins, Lifestyle modification"
                    ],
                    "mnemonics": {
                        "MONA": "Initial MI management - Morphine (pain), Oxygen (if hypoxic), Nitrates (vasodilation), Aspirin (antiplatelet)",
                        "HEART": "Risk stratification - History, ECG, Age, Risk factors, Troponin",
                        "TIMI": "Thrombolysis contraindications - Time >12hrs, Intracranial pathology, Major surgery, Ischemic stroke"
                    },
                    "clinicalPearls": [
                        "Silent MI common in diabetics and elderly due to autonomic neuropathy",
                        "Posterior MI shows ST depression in V1-V3, check posterior leads (V7-V9)",
                        "Right ventricular MI: Inferior MI + hypotension + clear lungs, avoid nitrates",
                        "Women may present with atypical symptoms: fatigue, nausea, back pain",
                        "Door-to-balloon time should be <90 minutes for STEMI"
                    ],
                    "practiceQuestions": [
                        {
                            "question": "A 55-year-old male with diabetes presents with crushing chest pain radiating to left arm for 2 hours. ECG shows ST elevation in leads II, III, aVF. BP is 90/60 mmHg with clear lung fields. What is the most appropriate immediate management?",
                            "options": [
                                "IV nitrates and morphine",
                                "IV fluids and avoid nitrates",
                                "Immediate thrombolysis",
                                "Beta-blocker administration"
                            ],
                            "correctAnswer": 1,
                            "explanation": "This is inferior wall MI with likely RV involvement (hypotension + clear lungs). RV infarction is preload-dependent, so IV fluids are needed. Nitrates are contraindicated as they reduce preload and can cause severe hypotension."
                        },
                        {
                            "question": "A 60-year-old smoker presents with chest pain for 6 hours. ECG shows ST depression in V2-V4. Troponin I is elevated. What is the diagnosis?",
                            "options": [
                                "STEMI",
                                "NSTEMI",
                                "Unstable angina",
                                "Stable angina"
                            ],
                            "correctAnswer": 1,
                            "explanation": "NSTEMI is characterized by elevated cardiac biomarkers (troponin) with ECG changes that do not meet STEMI criteria. ST depression and T wave inversion are common findings."
                        },
                        {
                            "question": "Which of the following is an absolute contraindication to thrombolytic therapy?",
                            "options": [
                                "Age >75 years",
                                "Recent ischemic stroke within 3 months",
                                "Uncontrolled hypertension (BP 180/110)",
                                "Pregnancy"
                            ],
                            "correctAnswer": 1,
                            "explanation": "Recent ischemic stroke within 3 months is an absolute contraindication to thrombolysis due to high risk of hemorrhagic transformation. Age >75, uncontrolled HTN, and pregnancy are relative contraindications."
                        }
                    ]
                },
                {
                    "id": "card-002",
                    "title": "Heart Failure",
                    "keyPoints": [
                        "Definition: Inability of heart to pump sufficient blood to meet metabolic demands",
                        "Classification: HFrEF (EF <40%, systolic dysfunction) vs HFpEF (EF >50%, diastolic dysfunction)",
                        "NYHA functional classification: I (no symptoms), II (symptoms with moderate activity), III (symptoms with minimal activity), IV (symptoms at rest)",
                        "Common causes: IHD, HTN, valvular disease, cardiomyopathy, arrhythmias",
                        "Clinical features: Dyspnea, orthopnea, PND, pedal edema, fatigue, S3 gallop, elevated JVP",
                        "Diagnosis: Clinical assessment + BNP/NT-proBNP (>400 pg/mL) + Echocardiography (EF assessment)",
                        "Acute management: Oxygen, IV diuretics (furosemide), vasodilators (nitrates), treat underlying cause",
                        "Chronic HFrEF management: ACE-I/ARB + Beta-blocker + MRA (spironolactone) + SGLT2i + Diuretics",
                        "Device therapy: CRT (for LBBB + EF <35%), ICD (for EF <35% with high SCD risk)",
                        "Advanced therapy: LVAD (bridge to transplant), Heart transplantation (end-stage HF)"
                    ],
                    "mnemonics": {
                        "FACES": "Common causes - Failure (pump), Arrhythmia, Coronary disease, Endocrine, Septal defects",
                        "ABCD": "HF management - ACE-I/ARB, Beta-blocker, aldosterone antagonist (MRA), Diuretics",
                        "CHAMP": "Decompensation triggers - Cardiac (MI, arrhythmia), Hypertension, Anemia, Medication non-compliance, Pulmonary embolism"
                    },
                    "clinicalPearls": [
                        "BNP <100 pg/mL essentially rules out HF (high negative predictive value)",
                        "Start beta-blockers only after stabilization, not in acute decompensation",
                        "Spironolactone improves mortality in NYHA III-IV HFrEF",
                        "HFpEF management focuses on treating comorbidities (HTN, AF, DM)",
                        "Avoid NSAIDs and CCBs (except amlodipine) in HF patients"
                    ],
                    "practiceQuestions": [
                        {
                            "question": "A 65-year-old with known HFrEF (EF 30%) presents with acute dyspnea, bilateral crackles, and BP 160/100. What is the most appropriate initial treatment?",
                            "options": [
                                "Start beta-blocker",
                                "IV furosemide and nitrates",
                                "Increase oral diuretics",
                                "Emergency dialysis"
                            ],
                            "correctAnswer": 1,
                            "explanation": "Acute decompensated HF with pulmonary edema requires IV loop diuretics (furosemide) for rapid diuresis and IV nitrates for preload reduction and BP control. Beta-blockers should not be started during acute decompensation."
                        },
                        {
                            "question": "Which medication has been shown to reduce mortality in HFrEF?",
                            "options": [
                                "Digoxin",
                                "Furosemide",
                                "Spironolactone",
                                "Amlodipine"
                            ],
                            "correctAnswer": 2,
                            "explanation": "Spironolactone (MRA) has proven mortality benefit in HFrEF, especially in NYHA III-IV. Digoxin improves symptoms but not mortality. Furosemide is for symptom control. Amlodipine is safe but doesn't reduce mortality."
                        }
                    ]
                },
                {
                    "id": "card-003",
                    "title": "Hypertension",
                    "keyPoints": [
                        "Definition: BP ≥140/90 mmHg on 2 separate occasions (ACC/AHA: ≥130/80)",
                        "Classification: Stage 1 (140-159/90-99), Stage 2 (≥160/100), Hypertensive emergency (≥180/120 with organ damage)",
                        "Primary HTN (95%): Essential, multifactorial etiology",
                        "Secondary HTN (5%): Renal disease, renovascular, endocrine (Conn's, Cushing's, pheochromocytoma), drugs, coarctation",
                        "Target organ damage: LVH, retinopathy, nephropathy, stroke, CAD",
                        "Lifestyle modifications: DASH diet, salt restriction (<2g/day), weight loss, exercise, limit alcohol",
                        "First-line drugs: ACE-I/ARB, CCB, Thiazide diuretics",
                        "Compelling indications: DM/CKD (ACE-I/ARB), Post-MI (Beta-blocker + ACE-I), HF (ACE-I + BB + MRA)",
                        "Hypertensive emergency: Reduce BP by 25% in first hour, then to 160/100 in 2-6 hours using IV agents",
                        "Resistant HTN: Add spironolactone, screen for secondary causes"
                    ],
                    "mnemonics": {
                        "ABCD": "Antihypertensive classes - ACE-I/ARB, Beta-blocker, CCB, Diuretic",
                        "CHARMS": "Secondary HTN causes - Coarctation, Hyperaldosteronism, Renal artery stenosis, Medications, Sleep apnea"
                    ],
                    "clinicalPearls": [
                        "White coat HTN: Elevated in clinic, normal at home (confirm with ABPM)",
                        "Masked HTN: Normal in clinic, elevated at home (higher CV risk)",
                        "ACE-I preferred in DM/CKD for renoprotection",
                        "Avoid beta-blockers as first-line in uncomplicated HTN",
                        "Check for postural hypotension in elderly before intensifying treatment"
                    ],
                    "practiceQuestions": [
                        {
                            "question": "A 45-year-old diabetic with HTN and proteinuria. Which antihypertensive is most appropriate?",
                            "options": [
                                "Amlodipine",
                                "Atenolol",
                                "Lisinopril",
                                "Hydrochlorothiazide"
                            ],
                            "correctAnswer": 2,
                            "explanation": "ACE inhibitors (lisinopril) are first-line in diabetic nephropathy due to renoprotective effects beyond BP control. They reduce proteinuria and slow CKD progression."
                        }
                    ]
                }
            ]
        },
        {
            "id": 2,
            "title": "Respiratory Medicine",
            "topics": [
                {
                    "id": "resp-001",
                    "title": "Asthma",
                    "keyPoints": [
                        "Chronic inflammatory airway disease with reversible airflow obstruction and bronchial hyperresponsiveness",
                        "Triggers: Allergens (dust, pollen), exercise, cold air, infections, NSAIDs, beta-blockers, stress",
                        "Pathophysiology: Type 1 hypersensitivity → mast cell degranulation → bronchospasm, inflammation, mucus production",
                        "Clinical features: Episodic wheeze, dyspnea, chest tightness, cough (worse at night/early morning)",
                        "Diagnosis: Spirometry showing FEV1/FVC <70% with reversibility >12% (or >200mL) post-bronchodilator",
                        "Peak flow variability >20% supports diagnosis",
                        "Step-wise management: Step 1 (SABA PRN) → Step 2 (+ low-dose ICS) → Step 3 (+ LABA) → Step 4 (medium-dose ICS/LABA) → Step 5 (high-dose + add-ons)",
                        "Acute exacerbation: Oxygen, nebulized SABA + ipratropium, systemic steroids, IV magnesium if severe",
                        "Severe asthma: Silent chest, inability to speak, RR >30, HR >120, PEFR <33% predicted",
                        "Good control: Minimal symptoms, normal activity, PEFR >80% predicted, rare exacerbations"
                    ],
                    "mnemonics": {
                        "ASTHMA": "Triggers - Allergens, Smoke, Temperature, Hormones, Meds (NSAIDs), Activity",
                        "SABA": "Acute management - Salbutamol, Assess severity, Beta-agonist nebulized, Admit if severe"
                    },
                    "clinicalPearls": [
                        "Silent chest in acute asthma indicates life-threatening severity",
                        "ICS are cornerstone of chronic management, reduce exacerbations",
                        "Never use LABA as monotherapy (increases mortality)",
                        "Aspirin-exacerbated respiratory disease (AERD): Asthma + nasal polyps + aspirin sensitivity",
                        "Check inhaler technique at every visit"
                    ],
                    "practiceQuestions": [
                        {
                            "question": "A 25-year-old with known asthma presents with severe dyspnea, unable to complete sentences, RR 32, HR 125, silent chest on auscultation. What is the most appropriate immediate management?",
                            "options": [
                                "Oral prednisolone and discharge",
                                "Nebulized salbutamol and reassess",
                                "Oxygen, nebulized bronchodilators, IV steroids, consider ICU",
                                "Inhaled corticosteroids"
                            ],
                            "correctAnswer": 2,
                            "explanation": "This is life-threatening asthma (silent chest, inability to speak, tachypnea, tachycardia). Requires aggressive management with high-flow oxygen, continuous nebulized bronchodilators, IV steroids, and ICU consideration for possible intubation."
                        }
                    ]
                },
                {
                    "id": "resp-002",
                    "title": "COPD",
                    "keyPoints": [
                        "Progressive airflow limitation due to chronic bronchitis and/or emphysema",
                        "Main risk factor: Smoking (>20 pack-years), also biomass fuel, alpha-1 antitrypsin deficiency",
                        "Chronic bronchitis: Productive cough for ≥3 months in 2 consecutive years",
                        "Emphysema: Destruction of alveolar walls → air trapping, hyperinflation",
                        "Clinical features: Progressive dyspnea, chronic cough, sputum production, wheeze, barrel chest",
                        "Diagnosis: Post-bronchodilator FEV1/FVC <0.7 on spirometry",
                        "GOLD classification: Mild (FEV1 ≥80%), Moderate (50-79%), Severe (30-49%), Very severe (<30%)",
                        "Stable COPD: SABA/SAMA PRN → LABA/LAMA → LABA+LAMA → add ICS if frequent exacerbations",
                        "Acute exacerbation: Increased dyspnea, sputum volume/purulence → Oxygen (target 88-92%), nebulized bronchodilators, steroids, antibiotics if purulent",
                        "Long-term oxygen therapy (LTOT): If PaO2 <55 mmHg or <60 with cor pulmonale, improves survival"
                    ],
                    "mnemonics": {
                        "COPD": "Features - Cough, Obstruction, Pink puffer/Blue bloater, Dyspnea",
                        "GOLD": "Severity grading - Grade 1-4 based on FEV1"
                    },
                    "clinicalPearls": [
                        "Avoid high-flow oxygen in COPD (risk of CO2 retention), target SpO2 88-92%",
                        "ICS increases pneumonia risk in COPD, use only if frequent exacerbations",
                        "Alpha-1 antitrypsin deficiency: Early-onset emphysema, lower lobe predominant",
                        "Smoking cessation is the only intervention that slows FEV1 decline",
                        "NIV indicated if pH <7.35 despite optimal medical therapy"
                    ],
                    "practiceQuestions": [
                        {
                            "question": "A 65-year-old smoker with COPD presents with increased dyspnea and purulent sputum. ABG shows pH 7.32, PaCO2 65, PaO2 55 on 4L O2. What is the next step?",
                            "options": [
                                "Increase oxygen to 10L",
                                "Start NIV with BiPAP",
                                "Immediate intubation",
                                "Reduce oxygen to 2L"
                            ],
                            "correctAnswer": 1,
                            "explanation": "Acute COPD exacerbation with respiratory acidosis (pH <7.35) despite medical therapy is an indication for NIV (BiPAP). This can prevent intubation and improve outcomes. Increasing oxygen can worsen hypercapnia."
                        }
                    ]
                }
            ]
        },
        {
            "id": 3,
            "title": "Gastroenterology",
            "topics": [
                {
                    "id": "gi-001",
                    "title": "Peptic Ulcer Disease",
                    "keyPoints": [
                        "Mucosal break in stomach (gastric ulcer) or duodenum (duodenal ulcer)",
                        "Main causes: H. pylori infection (70-90%), NSAIDs, stress (ICU patients)",
                        "Duodenal ulcer: Pain 2-3 hours after meals, relieved by food, more common",
                        "Gastric ulcer: Pain worsened by food, associated with weight loss",
                        "Diagnosis: Upper GI endoscopy with biopsy (rule out malignancy in GU), H. pylori testing (urea breath test, stool antigen, biopsy)",
                        "H. pylori eradication: Triple therapy (PPI + Clarithromycin + Amoxicillin) for 14 days OR Quadruple therapy (PPI + Bismuth + Tetracycline + Metronidazole)",
                        "NSAID-induced: Stop NSAID, PPI therapy, switch to COX-2 selective if needed",
                        "Complications: Bleeding (most common), perforation, gastric outlet obstruction, malignant transformation (GU only)",
                        "Zollinger-Ellison syndrome: Gastrinoma → multiple refractory ulcers, diarrhea, high gastrin levels",
                        "Confirm eradication: Urea breath test or stool antigen 4-6 weeks after treatment"
                    ],
                    "mnemonics": {
                        "GASTRIC": "Ulcer causes - Gastrinoma, Aspirin/NSAIDs, Smoking, Trauma, Reflux, Infection (H. pylori), Corticosteroids",
                        "PACED": "PUD complications - Perforation, Anemia, Cancer (GU), Erosion/bleeding, Duodenal obstruction"
                    },
                    "clinicalPearls": [
                        "All gastric ulcers need biopsy to rule out malignancy, DU rarely malignant",
                        "Posterior DU can erode into gastroduodenal artery → massive bleeding",
                        "Anterior DU perforation → pneumoperitoneum (air under diaphragm on CXR)",
                        "Triple therapy failure rate increasing due to clarithromycin resistance",
                        "PPI should be taken 30 minutes before meals for optimal effect"
                    ],
                    "practiceQuestions": [
                        {
                            "question": "A 50-year-old presents with epigastric pain relieved by food. Endoscopy shows duodenal ulcer. H. pylori test positive. What is the most appropriate treatment?",
                            "options": [
                                "PPI alone for 8 weeks",
                                "PPI + Clarithromycin + Amoxicillin for 14 days",
                                "H2 blocker for 4 weeks",
                                "Surgery"
                            ],
                            "correctAnswer": 1,
                            "explanation": "H. pylori-positive duodenal ulcer requires eradication therapy with triple therapy: PPI + Clarithromycin + Amoxicillin for 14 days. This heals the ulcer and prevents recurrence."
                        }
                    ]
                }
            ]
        }
    ],
    "quickRevision": {
        "highYieldTopics": [
            "Acute Coronary Syndrome management and ECG interpretation",
            "Heart Failure classification (HFrEF vs HFpEF) and treatment",
            "Asthma vs COPD differentiation and management",
            "Hypertension target organ damage and drug selection",
            "Peptic ulcer disease H. pylori eradication",
            "Acute exacerbation management (Asthma, COPD, HF)",
            "ECG patterns in MI (STEMI locations)",
            "Spirometry interpretation",
            "Antihypertensive drug compelling indications",
            "PUD complications and management"
        ],
        "importantDrugs": [
            {
                "name": "Aspirin",
                "class": "Antiplatelet",
                "indication": "ACS, stroke prevention, post-MI",
                "dose": "75-325 mg/day",
                "sideEffects": "GI bleeding, Reye's syndrome (children)",
                "contraindication": "Active bleeding, severe liver disease"
            },
            {
                "name": "Atorvastatin",
                "class": "Statin",
                "indication": "Dyslipidemia, post-ACS, DM",
                "dose": "10-80 mg/day",
                "sideEffects": "Myalgia, elevated LFTs, rhabdomyolysis (rare)",
                "monitoring": "LFTs, CK if symptomatic"
            },
            {
                "name": "Lisinopril",
                "class": "ACE Inhibitor",
                "indication": "HTN, HF, post-MI, diabetic nephropathy",
                "dose": "5-40 mg/day",
                "sideEffects": "Dry cough, hyperkalemia, angioedema",
                "contraindication": "Pregnancy, bilateral RAS, angioedema history"
            },
            {
                "name": "Metoprolol",
                "class": "Beta-blocker",
                "indication": "HTN, HF, post-MI, angina",
                "dose": "25-200 mg/day",
                "sideEffects": "Bradycardia, fatigue, bronchospasm",
                "contraindication": "Asthma, severe bradycardia, decompensated HF"
            },
            {
                "name": "Furosemide",
                "class": "Loop diuretic",
                "indication": "Acute pulmonary edema, HF, fluid overload",
                "dose": "20-80 mg IV/PO",
                "sideEffects": "Hypokalemia, ototoxicity, hypovolemia",
                "monitoring": "Electrolytes, renal function"
            },
            {
                "name": "Salbutamol",
                "class": "Short-acting beta-2 agonist",
                "indication": "Acute asthma/COPD, bronchospasm",
                "dose": "2.5-5 mg nebulized or 2 puffs MDI",
                "sideEffects": "Tremor, tachycardia, hypokalemia",
                "note": "Rescue medication, not for chronic use alone"
            },
            {
                "name": "Omeprazole",
                "class": "Proton pump inhibitor",
                "indication": "PUD, GERD, H. pylori eradication",
                "dose": "20-40 mg/day",
                "sideEffects": "Headache, diarrhea, increased fracture risk (long-term)",
                "note": "Take 30 min before meals"
            }
        ],
        "differentialDiagnosis": [
            {
                "presentation": "Chest Pain",
                "differentials": [
                    "ACS (MI, unstable angina)",
                    "Aortic dissection",
                    "Pulmonary embolism",
                    "Pneumothorax",
                    "GERD",
                    "Costochondritis",
                    "Pericarditis"
                ],
                "redFlags": "Radiation to arm/jaw, diaphoresis, ST changes, elevated troponin"
            },
            {
                "presentation": "Acute Dyspnea",
                "differentials": [
                    "Acute pulmonary edema (HF)",
                    "Asthma exacerbation",
                    "COPD exacerbation",
                    "Pneumonia",
                    "Pulmonary embolism",
                    "Pneumothorax",
                    "Anaphylaxis"
                ],
                "redFlags": "Hypoxia, tachypnea, altered mental status, hemodynamic instability"
            }
        ]
    }
}